The role of interferons in the treatment of osteosarcoma

Pediatric Blood and Cancer

Volumn 54, Issue 3, 2010, Pages 350-354

  Whelan, Jeremy ^a   Patterson, Daniel ^a   Perisoglou, Martha ^a   Bielack, Stefan ^b   Marina, Neyssa ^c   Smeland, Sigbjorn ^d   Bernstein, Mark ^e  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b KLINIKUM STUTTGART   (Germany)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cytokines; Interferon; Osteosarcoma; Treatment

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DACTINOMYCIN; DOXORUBICIN; GAMMA INTERFERON; METHOTREXATE; PEGINTERFERON; PEGINTERFERON ALPHA2A;

ADJUVANT THERAPY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; GLIOMA; HAIR LOSS; HUMAN; HYPERHIDROSIS; IN VITRO STUDY; INJECTION SITE PAIN; KAPOSI SARCOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLE STIFFNESS; NATURAL KILLER CELL; NONHUMAN; OSTEOSARCOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; XENOGRAFT;

ANIMALS; BONE NEOPLASMS; HUMANS; INTERFERON ALFA-2B; INTERFERONS; OSTEOSARCOMA;

EID: 76749141740     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22136     Document Type: Review

References (50)

1. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-1606.
2. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 2006;32: 423-435.
3. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
4. Whelan J, Weeden S, Uscinska B, et al. Localised extremity osteosarcoma: Mature survival data from two European Osteosarcoma Intergroup randomised clinical trials. ProcAmClin Oncol 2000;19:552 (abstr 2175).
5. Bacci GBA, Longhi A, Ferrari S, et al. Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 2005; 44:748-755.
6. Chou AJMP, Wexler LH, Gorlick RG, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: The Memorial Sloan-Kettering Cancer Center experience. Cancer 2005;104:2214-2221.
7. Kempf-Bielack BBS, Jürgens H, Branscheid D, et al. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23:559-568.
8. Miles DWPT. Biologically based therapies. In: Souhami RLTI, Hohenberger P, Horiot JC, editors. Oxford Textbook of Oncology, 2nd edition: Oxford University Press; 2002. pp 835-851.
9. Lindner D. Interferons as antiangiogenic agents. Curr Oncol Rep 2002;4:510-514.
10. Uzé G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: Cloning and expression of its cDNA. Cell 1990;60:225-234.
11. Issacs A Lindenmann J. Virus interference: The interferon. Proc R Soc Ser B Biol Sci 1957;147:258-267.
12. Fossa S. Interferons. In: Gore MRP, editor. Immunotherapy in cancer: John Wiley and Sons Ltd; 1996. pp 11-21.
13. Kirkwood J. Pharmacology of cancer biotherapeutics. In: al De, editor. Cancer principles and practice of oncology, 6th edition; 2001. pp 461-469.
14. Gresser I. Antitumour effects of interferons: Past, present and future. Br J Haematol 1991;79:1-5.
15. Strander H, Cantell K, Carlstrom G, et al. Clinical and laboratory investigations on man: Systemic administration of potent interferon to man. J Natl Cancer Inst 1973;51:733-742.
16. Mey U, Strehl J, Gorschlüter M, et al. Advances in the treatment of hairy-cell leukaemia. Lancet Oncol 2003;4:86-94.
17. Baccarani M, Russo D, Rosti G, et al. Interferon-alfa for chronic myeloid leukemia. Semin Hematol 2003;40:22-33.
18. Brandt L, Kimby E, Nygren P, et al. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncol 2001;40:213-223.
19. Bjorkstrand B, Svensson H, Goldschmidt H, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001;27:511-515.
20. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006;42:1014-1030.
21. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006;17:325-337.
22. Blackhall FH, Shepherd FA. Small cell lung cancer and targeted therapies. Curr Opin Oncol 2007;19:103-108.
23. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 1994;12:2321-2326.
24. Kelly K, Crowley JJ, Bunn PAJ, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study. J Clin Oncol 1995;13:2924-2930.
25. Atzpodien J, Lopez Hanninen E, Kirchner H, et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995;13:497-501.
26. MRC. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353: 14-17.
27. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferonalpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003;29: 241-252.
28. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-126.
29. Krown S. AIDS-associated Kaposi's sarcoma: Is there still a role for interferon alfa? Cytokine Growth Factor Rev 2007;18:395-402.
30. Ohno M, Natsume A, Fujii M, et al. Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma. Pediatr Blood Cancer 2009; Mar 3 [Epub ahead of print].
31. Hall G, Brown J, Coleman R, et al. Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer 2004;91:621-626.
32. Skelton L. The effective treatment of basal cell carcinoma. Br J Nurs 2009;18:346, 348-350.
33. Bukowski RM, Tendler C, Cutler D, et al.Treating cancer withPEG Intron: Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002;95:389-396.
34. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study. J Clin Oncol 2002;20:3841-3849.
35. Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion. Cancer 2008;112:982-994.
36. Barlow C, Priebe C, Mulliken J, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998;132:527-530.
37. Strander H, Einhorn S. Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer 1977;19:468-473.
38. Crane JL, Jr., Glasgow LA, Kern ER, et al. Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J Natl Cancer Inst 1978;61:871-874.
39. Glasgow L, Crane JJ, Kern E. Antitumor activity of interferon against murine osteogenic sarcoma cells in vitro. J Natl Cancer Inst 1978;60:659-666.
40. Masuda S, Fukuma H, Beppu Y. Antitumor effect of human leukocyte interferon on human osteosarcoma transplanted into nude mice. Eur J Cancer Clin Oncol 1983;19:1521-1528.
41. Brosjo O, Bauer HC, Brostrom LA, et al. Influence of human alphainterferon on four human osteosarcoma xenografts in nude mice. Cancer Res 1985;45:5598-5602.
42. Manara M, Serra M, Benini S, et al. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol 2004;24:365-372.
43. Strander H. Interferons and osteosarcoma. Cytokine Growth Factor Rev 2007;18:373-380.
44. Jia SF, Kleinerman ES. Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines. Lymphokine Cytokine Res 1991;10:281-284.
45. Kleinerman ES, Jia SF, Griffin J, et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration. J Clin Oncol 1992;10:1310-1316.
46. Muller CR, Smeland S, Bauer HC, et al. Interferon-alpha is the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncol 2005;44:475-480.
47. Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995;34:877-880.
48. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a Cooperative German/Austrian study. J Clin Oncol 1984;2:617-624.
49. Ito H, Murakami K, Yanagawa T, et al. Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma: Case reports. Cancer 1980;46:1562-1565.
50. Edmonson JH, Long HJ, Frytak S, et al. Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas. Cancer Treat Rep 1987;71:747-748.